Risk Management of Building Personnel Expertise While Starting and Growing Cell and Gene Therapy Biotechnology Companies
Author: Tamer Helmy, Biotech-Pharma Consultant, Quality Vigilance.
Summary
The cell and gene therapy (CGT) industry is revolutionizing medicine with therapies capable of treating rare and life-threatening diseases. However, launching and scaling a CGT biotech company involves navigating complex risks—particularly those associated with building personnel expertise. This whitepaper outlines how talent acquisition, integrating personnel in quality systems, and organizational culture intersect to safeguard patient safety and ensure sustainable business outcomes.
Introduction
Cell and gene therapies represent a paradigm shift in how we treat diseases, requiring precise processes and highly specialized knowledge. For about fifteen years, CGT has evolved and reformed drug development and the hopes of countless patients. Unlike traditional pharmaceuticals, CGT products are often individualized, time-sensitive, and biologically complex. As such, personnel expertise is not just a key asset—it is a fundamental risk factor. For early-stage CGT companies, missteps in hiring, training, or quality oversight can have profound implications.
From my personal experience, talent vary in their capabilities and a professional with limited experience, but high enthusiasm can be a great candidate for learning and development opportunities. On the other hand, an experienced professional, especially in a start-up environment can be a great asset to a company in the discovery stage. Several times I witnessed associates join an organization with good experience in commercial pharmaceutical manufacturing and they expect to operate the same process in a development organization. A risk could arise from the lack of experience in the start-up world as the regulatory expectations are not similar.
The price for hiring associates with only heavy commercial experience becomes evident in obstructing development and leveraging undue pressure that may stifle innovation. For example, in the development stage, there might not be enough batches to perform all the stability timepoints necessary for submissions. Hiring talent with appropriate experience, training them and providing them with the necessary leadership and guidance is crucial for the success of CGT organizations. Furthermore, in the early stages, close collaborations between Research and development, CMC, operations and quality is crucial.
Below is a discussion of risk-mitigation strategies to successfully approach the challenge of who to hire and how to integrate brining onboard the best industry associates who fit in the specific CGT environment.
Contact: [email protected]
Download '.pdf' Format of the whitepaper.
